Literature DB >> 9933048

Results of high-energy transurethral microwave thermotherapy in patients categorized according to the American Society of Anesthesiologists operative risk classification.

F C D'Ancona1, A K van der Bij, E A Francisca, H Kho, F M Debruyne, L A Kiemeney, J J de la Rosette.   

Abstract

OBJECTIVES: To evaluate the relation between the American Society of Anesthesiologists (ASA) classification and response to transurethral microwave thermotherapy (TUMT) in patients with lower urinary tract symptoms and benign prostatic hyperplasia (BPH).
METHODS: Two hundred forty-seven patients with symptomatic BPH treated with high-energy TUMT were scored retrospectively for ASA status. Student's t test was used to determine differences in improvement at each point of follow-up between patients classified as ASA 1 or 2 and patients classified as ASA 3 or 4. Logistic regression analysis was performed to assess the predictive value of ASA status for response using the World Health Organization response evaluation criteria for International Prostate Symptom Score, maximal flow rate, and urodynamic obstruction.
RESULTS: There was a significant improvement in objective and subjective parameters at 12, 26, and 52 weeks of follow-up in both ASA 1 and 2 patients and ASA 3 and 4 patients. There was no difference in objective and subjective improvement between both groups at each point of follow-up. Objective and subjective improvement in ASA 3 and 4 patients with cardiovascular disease and ASA 3 and 4 patients with noncardiovascular disease was the same, although patients with cardiovascular disease received less energy during TUMT. Using logistic regression analysis, ASA classification was not predictive of response after high-energy TUMT.
CONCLUSIONS: There is no relation between ASA classification and outcome after high-energy TUMT. Because these patients are considered at high risk of perioperative complications and postoperative morbidity, TUMT could contribute considerably to the treatment of BPH in this specific group of patients.

Entities:  

Mesh:

Year:  1999        PMID: 9933048     DOI: 10.1016/s0090-4295(98)00502-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

Review 1.  Transurethral microwave thermotherapy in benign prostatic hyperplasia.

Authors:  P Minnee; F M Debruyne; J J de la Rosette
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

2.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

3.  Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.

Authors:  J Curtis Nickel; Lorne Aaron; Jack Barkin; Dean Elterman; Mahmoud Nachabé; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2018-10       Impact factor: 1.862

4.  The safety and efficacy of transurethral microwave therapy in high-risk catheter-dependent men.

Authors:  Theodore R Saitz; Michael J Conlin; Christopher D Tessier; Thomas R Hatch
Journal:  Turk J Urol       Date:  2018-11-19

5.  UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.

Authors:  Dean Elterman; Mélanie Aubé-Peterkin; Howard Evans; Hazem Elmansy; Malek Meskawi; Kevin C Zorn; Naeem Bhojani
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.